{"id":64948,"date":"2026-05-11T12:04:48","date_gmt":"2026-05-11T04:04:48","guid":{"rendered":"https:\/\/flcube.com\/?p=64948"},"modified":"2026-05-11T12:04:49","modified_gmt":"2026-05-11T04:04:49","slug":"nhsa-launches-2026-nrdl-adjustment-with-expanded-eligibility-criteria-and-revised-weight-standards","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64948","title":{"rendered":"NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards"},"content":{"rendered":"\n

The National Healthcare Security Administration (NHSA)<\/strong> has released its draft 2026 Work Plan for Adjusting the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List<\/strong> alongside the Commercial Health Insurance Innovative Drug List (CHIDL)<\/strong>, officially commencing the annual National Reimbursement Drug List (NRDL)<\/strong> adjustment process.<\/p>\n\n\n\n

Key Regulatory Changes<\/h2>\n\n\n\n
Change Area<\/th>Previous Standard<\/th>2026 Adjustment<\/th><\/tr><\/thead>
Eligibility Cut-off Date<\/strong><\/td>June 30<\/td>Official issuance date of final work plan<\/td><\/tr>
Application Timeline<\/strong><\/td>Standard schedule<\/td>Advanced by approximately one month<\/td><\/tr>
Adult Weight Standard<\/strong><\/td>60 kg<\/td>65 kg<\/td><\/tr>
Body Surface Area<\/strong><\/td>Previous standard<\/td>1.68 m\u00b2<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Major Policy Innovations<\/h2>\n\n\n\n

1. Flexible Drug Eligibility Window<\/h3>\n\n\n\n

The NHSA proposes shifting the exclusive drug eligibility deadline from the traditional June 30 cutoff to the official issuance date of the final adjustment work plan, providing greater flexibility for pharmaceutical manufacturers.<\/p>\n\n\n\n

2. Introduction of Pre-Application Mechanism<\/h3>\n\n\n\n

For the first time, drugs that have not yet received formal marketing approval but have completed technical review by application opening are permitted to pre-apply. This expands the submission window to include “drugs that have received marketing approval or completed technical review on or before the official issuance date of the work plan.”<\/p>\n\n\n\n

3. Expanded Off-List Drug Criteria<\/h3>\n\n\n\n

Three new pathways now qualify previously excluded drugs:<\/p>\n\n\n\n